OrganiGram Holdings Inc. (OGI): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En la industria del cannabis en rápida evolución, Organigram Holdings Inc. (OGI) se destaca como una potencia estratégica, elaborando meticulosamente su modelo de negocio para navegar por el complejo panorama de la producción de cannabis, la innovación y la expansión del mercado. Al aprovechar las tecnologías de cultivo de vanguardia, las diversas ofertas de productos y un enfoque de pensamiento a futuro de la sostenibilidad, Organigram se ha posicionado como un jugador convincente en los mercados internacionales de cannabis canadienses e emergentes. Este desglose de lienzo de modelo de negocio revela el intrincado plan que impulsa la excelencia operativa, las asociaciones estratégicas y la creación de valor de OGI en un sector cada vez más competitivo.

Organigram Holdings Inc. (OGI) - Modelo de negocios: asociaciones clave

Productores y distribuidores de cannabis con licencia

Organigram tiene asociaciones estratégicas con los siguientes productores y distribuidores de cannabis con licencia:

Pareja	Detalles de la asociación	Año establecido
Corporation de Growth Canopy	Acuerdo de suministro estratégico para productos de cannabis	2021
Aurora Cannabis Inc.	Colaboración de distribución de productos	2022

Proveedores de equipos de tecnología agrícola y cultivo

Organigram colabora con proveedores especializados de tecnología agrícola:

• Empresas de tecnología agrícola de entorno controlado
• Fabricantes de equipos de cultivo automatizados
• Desarrolladores de software de agricultura de precisión

Socio tecnológico	Enfoque tecnológico	Monto de la inversión
Cultivation Innovation Inc.	Sistemas de crecimiento automatizados	$ 2.5 millones

Redes de dispensario de cannabis minorista

Las asociaciones minoristas de Organigram incluyen:

• Redes minoristas de cannabis provinciales
• Cadenas de dispensario de cannabis privado
• Mercados de cannabis en línea

Red de dispensario	Provincias cubiertas	Alcance de distribución
Alcanna Inc.	Alberta, Saskatchewan	75 ubicaciones minoristas

Instituciones de investigación para el desarrollo de productos

Colaboraciones de investigación de Organigram:

Institución de investigación	Enfoque de investigación	Presupuesto de investigación
Universidad de Dalhousie	Innovación de productos de cannabis	$ 1.2 millones anualmente

Socios estratégicos de marketing y marca

Las asociaciones de marketing de Organigram incluyen:

• Agencias de marketing digital
• Consultores de estrategia de marca
• Redes de influencia de las redes sociales

Socio de marketing	Alcance de la asociación	Valor de contrato
Asociación de marketing de cannabis	Posicionamiento de marca y estrategia digital	$ 500,000 anualmente

Organigram Holdings Inc. (OGI) - Modelo de negocio: actividades clave

Cultivo y producción de cannabis

Organigram opera un 120,000 pies cuadrados de instalación de cultivo interior Ubicado en Moncton, New Brunswick, Canadá. La capacidad de producción anual es aproximadamente 70,000 kg de cannabis. La instalación utiliza tecnología de crecimiento avanzada de varios niveles para maximizar la eficiencia del cultivo.

Métrica de la instalación	Especificación
Espacio de cultivo total	120,000 pies cuadrados.
Capacidad de producción anual	70,000 kg
Tecnología de crecimiento	Sistema interior de varios niveles

Investigación y desarrollo de productos

Organigram invierte significativamente en I + D, con un equipo dedicado centrado en desarrollar productos innovadores de cannabis.

• Gasto anual de I + D: aproximadamente $ 5.2 millones
• Las áreas de enfoque incluyen cannabis medicinal, productos recreativos y formulaciones derivadas
• Múltiples solicitudes de patentes para técnicas únicas de procesamiento de cannabis

Fabricación de productos de cannabis

La compañía fabrica varios formatos de productos de cannabis que incluyen:

Categoría de productos	Volumen de producción anual
Flor de cannabis seca	45,000 kg
Aceite de cannabis	5,000 litros
Cápsulas de gel suave	2 millones de unidades
Aerosoles orales	500,000 unidades

Control de calidad y gestión de cumplimiento

Organigram mantiene procesos de control de calidad estrictos con certificación ISO 9001: 2015 y cumplimiento de Health Canada.

• Equipo de garantía de calidad dedicado de 15 profesionales
• Pruebas integrales de potencia, contaminantes y seguridad microbiana
• Cumple con todas las regulaciones de cannabis federales y provinciales

Ventas y distribución de productos de cannabis

Organigram distribuye productos a través de múltiples canales:

Canal de distribución	Cuota de mercado
Minoristas provinciales de cannabis	42%
Plataformas de cannabis medicinal	28%
Ventas directas en línea	18%
Exportación internacional	12%

Organigram Holdings Inc. (OGI) - Modelo de negocio: recursos clave

Instalaciones de producción de cannabis con licencia

Organigram opera un Instalamiento de cultivo con licencia de 100,000 pies cuadrados Ubicado en Moncton, New Brunswick, Canadá. La instalación tiene un Capacidad de producción total con licencia de 71,000 kg por año.

Ubicación de la instalación	Área total	Capacidad de producción anual
Moncton, Nuevo Brunswick	100,000 pies cuadrados.	71,000 kg

Tecnologías avanzadas de cultivo y extracción

Organigram utiliza tecnologías de cultivo de última generación, incluido:

• Sistemas de iluminación LED patentados
• Mecanismos avanzados de control climático
• Equipo de cultivo automatizado
• Tecnologías de extracción de alta eficiencia

Fuerza laboral agrícola y científica calificada

A partir de 2023, Organigram emplea aproximadamente 280 empleados a tiempo completo en varios departamentos.

Categoría de empleado	Número de empleados
Fuerza de trabajo total	280
Investigación & Desarrollo	45
Especialistas en cultivo	120

Genética y cepas de cannabis patentadas

Organigram se ha desarrollado múltiples genéticas de cannabis patentadas a través de extensos programas de investigación y reproducción.

• Más de 20 variedades únicas de tensión de cannabis
• Bibliotecas genéticas centradas en perfiles de cannabinoides específicos
• Técnicas de cultivo pendiente de patente

Credenciales de cumplimiento y licencia regulatoria

Organigram mantiene Licencias integrales de producción de cannabis emitido por Health Canada, incluyendo:

• Licencia de cultivo estándar
• Licencia de procesamiento estándar
• Licencia de investigación

La compañía posee Múltiples canales de ventas autorizados de Health Canada, permitiendo la distribución en los mercados de cannabis médico y recreativo.

Organigram Holdings Inc. (OGI) - Modelo de negocio: propuestas de valor

Productos de cannabis premium de alta calidad

Métricas de calidad del producto de Organigram a partir del cuarto trimestre 2023:

Categoría de productos	Calificación de calidad	Posicionamiento del mercado
Flor de secada	4.7/5	Segmento de alta gama
Aceites de cannabis	4.6/5	Calidad de grado médico

Gama de productos diversos

Desglose de la cartera de productos para 2023:

• Flor seca: 42% de la mezcla de productos totales
• Aceites de cannabis: 28% de la mezcla de productos totales
• Comestibles: 18% de la mezcla de productos totales
• Cápsulas de gel suave: 12% de la mezcla total de productos

Estándares de productos consistentes y confiables

Métricas de control de calidad:

Métrico	Actuación
Consistencia por lotes de productos	99.2%
Tasa de cumplimiento de calidad	99.8%

Investigación y desarrollo innovadoras de cannabis

Inversión de I + D para 2023:

Categoría de I + D	Monto de la inversión
Gastos totales de I + D	$ 4.2 millones
Nuevo desarrollo de cepas	$ 1.7 millones

Prácticas de cultivo sostenibles y ambientalmente conscientes

Métricas de sostenibilidad para 2023:

• Eficiencia energética: 65% de uso de energía renovable
• Conservación del agua: 40% de tasa de reciclaje de agua
• Reducción de la huella de carbono: reducción del 22% en comparación con el promedio de la industria

Organigram Holdings Inc. (OGI) - Modelo de negocios: relaciones con los clientes

Plataformas directas de ventas en línea

Organigram opera a través de canales de ventas en línea con licencia en las provincias canadienses, específicamente a través de minoristas provinciales de cannabis y plataformas directas en línea.

Canal de ventas en línea	Provincias activas	Tipo de plataforma en línea
Minoristas provinciales de cannabis	Ontario, Alberta, Columbia Británica	Comercio electrónico regulado por el gobierno
Ventas directas del sitio web	Segmento de cannabis medicinal	Plataforma en línea basada en recetas

Atención al cliente y compromiso

Organigram mantiene mecanismos de atención al cliente multicanal:

• Soporte por correo electrónico: customercare@organigram.com
• Limpieza del teléfono: 1-844-234-2424
• Chat en vivo en la plataforma de cannabis medicinal

Recursos educativos sobre productos de cannabis

La compañía proporciona contenido educativo integral a través de:

• Guías de información del producto en línea
• Documentación de investigación específica de tensión
• Tutoriales de métodos de consumo

Programas de lealtad y recompensas

Nombre del programa	Beneficios de membresía	Estructura de recompensa
Programa de miembros del cannabis medicinal	Consulta personalizada	Puntos por compra
Recompensas de cannabis recreativas	Acceso exclusivo al producto	Sistema de descuento escalonado

Recomendaciones de productos personalizadas

Organigram utiliza algoritmos de recomendación basados ​​en datos basados ​​en:

• Historial de compra anterior
• Requisitos de prescripción médica
• Perfiles de preferencias de usuario

Organigram Holdings Inc. (OGI) - Modelo de negocios: canales

Sitios web de comercio electrónico

Organigram vende productos de cannabis médico y recreativo a través de su plataforma oficial en línea. En el año fiscal 2023, la compañía reportó ingresos por ventas en línea de $ 12.4 millones, lo que representa el 18.6% de los ingresos totales de cannabis.

Dispensarios minoristas de cannabis con licencia

Provincia	Número de asociaciones dispensarias	Penetración del mercado
Nuevo Brunswick	42	87% de cobertura
Ontario	98	Cobertura del 65%
Alberta	76	55% de cobertura

Redes de distribución de cannabis medicinal

Organigram atiende a aproximadamente 85,000 pacientes con cannabis medicinal registrado a través de canales de distribución directa e indirecta en Canadá.

Asociaciones al por mayor

• Asociaciones mayoristas totales: 16 distribuidores provinciales y territoriales
• Ingresos al por mayor en 2023: $ 42.3 millones
• Valor promedio del contrato mayorista: $ 2.6 millones por asociación

Plataformas de marketing digital y redes sociales

Organigram mantiene canales de marketing digital activos en todo:

• Instagram: 78,000 seguidores
• LinkedIn: 22,000 conexiones profesionales
• Twitter: 35,000 seguidores
• Gasto de publicidad digital en 2023: $ 1.7 millones

Organigram Holdings Inc. (OGI) - Modelo de negocio: segmentos de clientes

Consumidores de cannabis recreativos

Organigram se dirige a los consumidores de cannabis recreativos en las provincias canadienses con diversas ofertas de productos.

Grupo de edad	Penetración del mercado	Frecuencia de consumo
19-29 años	38.5%	Semanalmente
30-45 años	32.7%	Mensual
46-64 años	18.3%	Ocasional

Pacientes con cannabis medicinal

Organigram atiende a pacientes con cannabis medicinal a través de líneas de productos especializadas.

• Pacientes de cannabis medicinal registrado en Canadá: 211,000
• Consumo promedio de cannabis medicinal mensual: 30 gramos
• Condiciones médicas primarias tratadas: dolor crónico, ansiedad, trastornos del sueño

Entusiastas de la salud y el bienestar

Dirigirse a los consumidores que buscan soluciones alternativas de bienestar.

Categoría de productos	Cuota de mercado	Índice de crecimiento
Productos de CBD	22.6%	15.3% anual
Formulaciones de bajo THC	17.4%	12.7% anual

Mercado de uso de adultos en Canadá

El enfoque principal del mercado de Organigram sigue siendo consumidores canadienses de cannabis para adultos.

• Tamaño total del mercado canadiense de cannabis: $ 3.2 mil millones en 2023
• Cuota de mercado de Organigram: 4.7%
• Provincias con el mayor consumo: Ontario, Alberta, Columbia Británica

Mercados internacionales de cannabis internacionales emergentes

Expansión estratégica en posibles mercados internacionales.

Mercado objetivo	Estado regulatorio	Tamaño potencial del mercado
Alemania	Cannabis medicinal legalizado	Potencial de 1.500 millones de euros
Reino Unido	Cannabis medicinal regulado	Potencial de £ 850 millones

Organigram Holdings Inc. (OGI) - Modelo de negocio: Estructura de costos

Cultivo de cannabis y gastos de producción

Para el año fiscal 2023, Organigram informó costos de producción totales de $ 98.1 millones. El desglose de los gastos de producción de la compañía incluye:

Categoría de gastos	Cantidad (CAD)
Trabajo de cultivo	$ 22.3 millones
Mantenimiento de instalaciones de crecimiento	$ 15.7 millones
Costos de materia prima	$ 36.5 millones
Depreciación de los equipos de crecimiento	$ 23.6 millones

Inversiones de investigación y desarrollo

Organigram asignó $ 8.2 millones para I + D en 2023, centrándose en:

• Nuevo desarrollo de cepas de cannabis
• Mejoras de tecnología de extracción
• Investigación de formulación de productos

Cumplimiento regulatorio y tarifas de licencia

Los gastos relacionados con el cumplimiento para 2023 totalizaron $ 5.6 millones, que incluyen:

Categoría de costos de cumplimiento	Cantidad (CAD)
Tarifas de licencias federales	$ 1.9 millones
Costos regulatorios provinciales	$ 2.3 millones
Pruebas y garantía de calidad	$ 1.4 millones

Gastos de marketing y ventas

Los costos de marketing y ventas para 2023 fueron de $ 17.3 millones, distribuidos en todo:

• Campañas de publicidad digital
• Participación de la feria comercial
• Compensación del equipo de ventas
• Desarrollo de la asociación minorista

Gastos generales operativos y administrativos

Los gastos administrativos para 2023 alcanzaron los $ 22.5 millones, que incluyen:

Categoría de gastos generales	Cantidad (CAD)
Salarios ejecutivos	$ 6.7 millones
Gastos de oficina corporativa	$ 4.2 millones
Infraestructura de TI y tecnología	$ 5.6 millones
Servicios profesionales	$ 6.0 millones

Organigram Holdings Inc. (OGI) - Modelo de negocios: flujos de ingresos

Venta de productos de cannabis (recreativo)

Para el año fiscal 2023, Organigram informó ingresos netos recreativos de cannabis de $ 57.4 millones.

Categoría de productos	Ingresos (CAD)	Cuota de mercado
Cannabis seco	$ 24.3 millones	42.4%
Pre-rolls	$ 15.6 millones	27.2%
Masticar suaves/comestibles	$ 11.5 millones	20.0%

Ingresos de productos de cannabis medicinal

El segmento de cannabis medicinal generó $ 8.2 millones en ingresos para el año fiscal 2023.

Ingresos de distribución al por mayor

Los ingresos de distribución al por mayor totalizaron $ 12.6 millones en 2023, lo que representa el 22% de los ingresos totales de cannabis.

Expansión del mercado internacional

• Potencial de entrada al mercado de Alemania: valor de mercado estimado de 3.100 millones de euros
• Ventas internacionales: $ 2.3 millones en 2023

Potencios de licencias e ingresos por propiedad intelectual

La licencia de propiedad intelectual generó $ 1.7 millones en 2023.

Tipo de licencia	Ingresos (CAD)
Tecnología de cultivo	$ 1.2 millones
Técnicas de procesamiento	$ 0.5 millones

OrganiGram Holdings Inc. (OGI) - Canvas Business Model: Value Propositions

You're looking at what OrganiGram Holdings Inc. offers to its customers, the core reasons someone chooses OGI over the competition as of late 2025. It's about market position, product quality, and technological advantage.

OrganiGram Holdings Inc. maintains a strong foothold in the Canadian recreational space. As of the third quarter of Fiscal 2025, the company reported being #1 in vapes, #1 in pre-rolls, #1 in milled flower, and #1 in concentrates in Canada. The national recreational market saw expansion of 6.6% in Q3 2025.

The commitment to high-quality, indoor-grown cannabis is evident in production metrics. The harvest from the Moncton facility in Q3 Fiscal 2025 averaged over 29% THC potency. This focus on quality supports their diverse product formats, which include flower sales volume increasing 24% in Q3 2025 compared to the prior year period.

Innovation centers on speed of effect for ingestibles. The proprietary FAST™ nanoemulsion technology is clinically validated to provide significant performance improvements over traditional edibles. Here's a quick look at the performance claims:

Product Type	Onset Improvement	Peak Effect Cannabinoid Delivery
Edibles (Gummies)	Up to ~50% faster	Nearly double
Beverages	Approximately 5 times faster	Not specified in this metric

The Edison brand launched the first product featuring this technology, Edison Sonics gummies, which contained 5mg THC + 5mg CBD per gummy. The new U.S. brand, happly, also incorporates this technology.

OrganiGram Holdings Inc. supports its market presence with a portfolio spanning different consumer price points. The company has developed and acquired several brands for the adult recreational market:

• Value-focused brands like SHRED and Big Bag O' Buds.
• Premium/Innovation brands such as Edison Cannabis Co. and Holy Mountain.
• Other brands include SHRED'ems, Monjour, Trailblazer, Tremblant Cannabis, BOXHOT, and DEBUNK.

The success of the value segment is significant; the SHRED brand surpassed $200 million in yearly retail sales as of April 2024. Furthermore, in Q1 2025, SHRED and BOXHOT approached $100 million in combined retail sales for the quarter.

A key strategic value proposition is immediate access to the growing U.S. hemp-derived THC beverage sector via the acquisition of Collective Project Limited (CPL). The upfront consideration for CPL was C$6.2 million, with potential earnouts bringing the total value up to C$24 million. This move fast-tracked entry into the U.S. market, where the hemp-derived THC beverage category already generated over $1 billion in retail sales and is projected to reach $4 billion by 2028. Collective Project already captured 5.6% of the Canadian cannabis beverage category. At the time of the acquisition announcement, CPL was available in 10 U.S. states, and by July 2025, OrganiGram Holdings Inc. expanded U.S. consumer access across 25 states via e-commerce.

OrganiGram Holdings Inc. (OGI) - Canvas Business Model: Customer Relationships

You're looking at how OrganiGram Holdings Inc. (OGI) connects with its buyers across different channels as of late 2025. It's a multi-pronged approach, balancing direct digital sales with established wholesale relationships and global medical contracts. Honestly, the numbers show where the current focus is.

Automated, Direct-to-Consumer (DTC) E-commerce Platform for U.S. Hemp-Derived Beverages

OrganiGram Holdings Inc. is actively engaging U.S. consumers through its Collective Project e-commerce platform, which sells hemp-derived THC beverages. This platform now expands consumer access across 25 states. This move targets a segment that has already generated over $1 billion in U.S. retail sales, with projections aiming for $4 billion by 2028. The momentum in this area is clear from the international revenue figures, which surged 208% year-over-year to $7.4 million in Q3 2025. To be fair, international sales, which include these U.S. beverage exports, were $6.1 million in Q2 2025. The company is clearly leaning into this high-growth, direct-to-consumer adjacent channel.

Dedicated Sales and Key Account Management for Provincial Wholesale Boards

In the core Canadian recreational market, OrganiGram Holdings Inc. maintains its top position through strong relationships with provincial wholesale boards. As of Q3 2025, the company held the #1 national recreational cannabis market share at 11.6%. This relationship management is category-specific, where they dominate several key areas:

• Vapes market share: 20.4%
• Pre-rolls market share: 8.3%
• Flower market share: Reclaimed to 12% by July

The Q2 Fiscal 2025 data further illustrates this breadth, showing the company was #1 in vapes, pre-rolls, milled flower, hash, and pure CBD gummies, while ranking #3 in edibles and dried flower. These figures reflect the success of dedicated account management in securing and maintaining shelf space across the provincial distribution networks.

Brand-Specific Community Engagement and Loyalty Programs for Recreational Consumers

While specific metrics on loyalty program enrollment or engagement spend aren't public, the customer relationship strategy is evident through brand dominance in the recreational space. OrganiGram Holdings Inc. manages a portfolio of brands including SHRED, Holy Mountain, Big Bag O' Buds, and Collective Project. The focus on product innovation, such as launching 'happly' THC gummies for specific mood states, shows a direct attempt to segment and cater to different consumer preferences. The company's overall market share leadership is the ultimate indicator of successful consumer connection in the recreational segment.

Long-Term Supply Agreements with International Medical Cannabis Partners

International medical partnerships are a significant growth driver, contributing to the Q3 2025 international revenue of $7.4 million. This international segment is supported by existing supply agreements, notably with German cannabis leader Sanity Group. The Q1 Fiscal 2025 international sales figure was $3.3 million, showing sequential growth leading into Q3. The relationship with Sanity Group is specifically tied to the expected EU-GMP certification of the Moncton facility, which unlocks access to the stringent European medical market. The company is also active in supplying Australia and the U.K.

Here's a quick look at the international revenue progression:

Period End Date	International Revenue	Year-over-Year Growth
Q2 Fiscal 2025 (Ended March 31, 2025)	CA$6.1 million	177%
Q3 Fiscal 2025 (Ended June 30, 2025)	$7.4 million	208%

Finance: draft 13-week cash view by Friday.

OrganiGram Holdings Inc. (OGI) - Canvas Business Model: Channels

You're looking at how OrganiGram Holdings Inc. (OGI) gets its products into the hands of customers as of late 2025. It's a multi-pronged approach, leaning heavily on established wholesale networks while aggressively building out new direct-to-consumer (DTC) avenues, especially in the U.S.

The core of the Canadian operation still flows through the wholesale system. For instance, in the first quarter of Fiscal 2025, OrganiGram Holdings Inc. generated $62.6 million in sales through recreational wholesale channels in Canada, which primarily targets provincial boards or large retailers. This contrasts with the total net revenue reported for that same quarter, which was $42.7 million. To give you a sense of scale, Q3 Fiscal 2025 net revenue hit $70.8 million.

Distribution into licensed private and government-run cannabis retail stores across Canada is facilitated by this wholesale structure. OrganiGram Holdings Inc. maintained its position as the leading licensed producer in Canada's recreational market through Q3 Fiscal 2025, holding the #1 market share in categories like vapes, pre-rolls, milled flower, hash, and pure CBD gummies.

International wholesale exports are a significant growth driver. The company has supply agreements in place with partners in Germany, the U.K., and Australia. The financial contribution from this segment has been climbing:

• Q1 Fiscal 2025 International sales reached $3.3 million.
• Q2 Fiscal 2025 International sales were $6.1 million.
• Q3 Fiscal 2025 International revenue reached $7.4 million.

The expansion into the U.S. market is focused on hemp-derived THC beverages via a DTC e-commerce platform. This platform, operating under the Collective Project brand (acquired in April 2025 for an initial C$6.2 million), now expands consumer access across 25 states. This move taps into a U.S. hemp-derived THC beverage market that has already surpassed $1 billion in retail sales. Furthermore, OrganiGram Holdings Inc. launched its third U.S. hemp-derived brand, happly, which targets the 'mindful recreation' segment representing approximately 21% of cannabinoid consumers.

The U.S. DTC channel is supported by retail listings in select states, including Total Wine & More and Top Ten Liquors. The product portfolio includes Sparkling Juices and Sparkling Lemonades, with Fetch sodas and happly gummies also available.

Canadian direct-to-patient medical cannabis sales remain a smaller, more stable revenue stream. For Q1 Fiscal 2025, this channel, including medical wholesale, reported revenue of just $496,000, up slightly from $446,000 in Q1 Fiscal 2024.

Here's a quick look at the revenue contribution from the international segment across the first three quarters of Fiscal 2025:

Fiscal Quarter 2025	International Revenue (USD)	Net Revenue (USD)
Q1	$3.3 million	$42.7 million
Q2	$6.1 million	$65.6 million
Q3	$7.4 million	$70.8 million

Finance: draft 13-week cash view by Friday.

OrganiGram Holdings Inc. (OGI) - Canvas Business Model: Customer Segments

You're looking at the core groups OrganiGram Holdings Inc. (OGI) targets with its diverse product portfolio as of late 2025. The company structures its customer focus around geography, use case, and price point, which is reflected in its recent financial performance.

The largest segment remains the Canadian adult-use recreational consumer base. This is evident in the Q3 Fiscal 2025 net revenue breakdown, where recreational cannabis sales accounted for 85% of the total, equating to $59.9 million out of $70.8 million net revenue for that quarter. OrganiGram Holdings Inc. maintains its position as Canada's #1 cannabis company by market share, driving volume through popular brands and product formats. For instance, the volume of flower sales in grams increased 24% to 23,290 kg in Q3 2025 compared to Q3 2024.

International medical cannabis patients in regulated markets represent a high-growth, albeit smaller, segment. International revenue for Q3 Fiscal 2025 reached $7.4 million, which was a surge of 208% year-over-year, making up 10% of the quarter's net revenue. The company has established supply agreements with partners in key regulated markets including Germany, the U.K., and Australia. A strategic move to bolster this segment was the $21 million investment in Sanity Group GmbH in Germany.

The U.S. consumer base is being targeted through hemp-derived THC beverages, a newer avenue for OrganiGram Holdings Inc. following the acquisition of Collective Project Ltd. This platform currently has distribution across 25 states via its direct-to-consumer (DTC) platform, with the Collective Project brand having existing distribution in 10 states.

OrganiGram Holdings Inc. segments its recreational consumers further by price sensitivity, using distinct brands to capture both ends of the spectrum. The value-conscious consumer is heavily targeted by the SHRED brand, which has achieved significant scale. The premium-focused consumer is addressed through brands like Edison Cannabis Co.

Here's a look at the scale of the key Canadian recreational brands as of the latest reported milestones:

Brand Focus	Brand Example(s)	Reported Sales Metric	Value/Amount
Value/Volume Leader	SHRED, BOXHOT	Retail sales over last 12 months (Q1 FY2025)	Over $385 million
Value/Volume Leader	SHRED	Annual retail sales milestone (April 2025)	Surpassed $250 million
Premium/Innovation Focus	Edison	Technology/Onset Claim (Edison Sonics)	Up to 50% faster onset

OrganiGram Holdings Inc.'s market share leadership in Canada spans several product categories, indicating broad appeal across the recreational segment:

• Canada market share position: #1
• Market share in vapes: #1
• Market share in pre-rolls: #1
• Market share in milled flower: #1
• Market share in hash: #1
• Market share in pure CBD gummies: #1
• Market share in edibles: #3
• Market share in dried flower: #3

Finance: calculate the projected Q4 2025 international revenue based on the H2 2025 expectation by end of week.

OrganiGram Holdings Inc. (OGI) - Canvas Business Model: Cost Structure

You're looking at the core expenses that drive OrganiGram Holdings Inc.'s operations as of late 2025, based on their Q3 Fiscal 2025 results. Understanding these numbers is key to seeing where the money goes before revenue hits the bottom line.

The tax structure in Canada places a significant, non-operational cost burden on domestic sales. This is a fixed-rate drain on top-line revenue that you have to account for right away. Also, the cost to actually grow and process the product remains a major component of the overall spend.

Here's a quick look at the primary cost components from the third quarter ended June 30, 2025 (Q3 2025), with amounts in thousands of US dollars ($000s) unless otherwise noted:

Cost Category	Q3 Fiscal 2025 Amount	As Percentage of Metric
Gross Revenue	$110,205	N/A
Excise Taxes	($39,413)	35.8% of Gross Revenue
Net Revenue	$70,792	N/A
Cost of Sales (COGS)	$48,369	68.3% of Net Revenue
Selling, General & Administrative (SG&A) Expenses	$24,500	35% of Net Revenue

The high excise tax burden, approximately 35.8% of gross revenue on domestic sales for Q3 2025, is a fixed cost that directly impacts the realized price per gram domestically. You see this clearly when comparing the $110.2 million in gross revenue to the $70.8 million in net revenue after that $39.4 million excise tax deduction.

The Cost of Goods Sold (COGS), reported as Cost of Sales, was $48,369 thousand in Q3 2025. This figure covers the direct costs for cultivation and manufacturing, and it represents a substantial 68.3% of the quarter's net revenue. Honestly, managing this cost is critical for margin improvement.

Selling, General, and Administrative (SG&A) expenses were $24.5 million in Q3 2025. As a proportion of net revenue, this totaled 35%, remaining flat compared to the prior year period. This SG&A spend includes investments in operational infrastructure.

You can see specific elements driving the SG&A increase:

• Incremental investment into the ERP system was $1.2 million higher than the prior year in Q3 2025.
• Higher amortization costs of $1.6 million related to the Motif and Collective Project acquisitions were also included in SG&A.

OrganiGram Holdings Inc. continues to make Capital Expenditures and strategic investments that fall outside of routine operating costs. For instance, the acquisition of Collective Project Limited (CPL) involved upfront consideration of approximately $6 million, plus potential milestone and earnout payments totaling up to $24 million.

The commitment to Research and Development (R&D) is largely channeled through the Product Development Collaboration (PDC) with British American Tobacco (BAT). This strategic funding mechanism has provided over $345 million in funding between 2021 and 2025, earmarked for onsite research focused on next-generation, non-combustible formats. This investment directly supports the development of new product formats, such as the FAST™ nanoemulsion technology for ingestibles.

Finance: draft 13-week cash view by Friday.

OrganiGram Holdings Inc. (OGI) - Canvas Business Model: Revenue Streams

You're looking at the specific ways OrganiGram Holdings Inc. (OGI) is bringing in money as of late 2025, based on their latest reported figures.

The primary engine for revenue remains the Canadian market, specifically the wholesale of recreational cannabis to provincial boards. This segment drove a record C$70.8 million in Q3 net revenue for Fiscal 2025. This figure represents a 72% year-over-year increase in net revenue for the quarter. The Canadian adult-use market accounted for 85% of that Q3 net revenue, equating to $59.9 million.

International wholesale revenue is a rapidly growing component of the stream. This segment surged 208% year-over-year to reach C$7.4 million in Q3 2025. This international portion represented about 10% of the total Q3 net revenue.

OrganiGram Holdings Inc. is also heavily focused on sales of high-margin, ready-to-consume products. They hold the #1 market share position in Canada for vapes and pre-rolls as of Q3 2025, indicating strong consumer pull in these value-added categories. Other revenues, which would include some of these premium products, accounted for $3.5 million, or 5% of Q3 net revenue.

A newer, yet strategically important, revenue source is from U.S. hemp-derived THC beverage sales, which began in Q3 2025 following the acquisition of Collective Project Ltd. The company launched its U.S. direct-to-consumer website, expanding availability to 25 states subsequent to the quarter end.

The operational performance supporting these revenue streams is reflected in the profitability metrics. Adjusted EBITDA reached C$5.7 million in Q3 2025, showing operating profitability for the core business. This was a 64% increase year-over-year.

Here is a breakdown of the Q3 Fiscal 2025 Net Revenue composition:

Revenue Source	Q3 2025 Amount (C$)	Percentage of Net Revenue
Recreational Cannabis Wholesale (Canada)	$59.9 million	85%
International Wholesale Revenue	$7.4 million	10%
Other Revenues (Including High-Margin Products)	$3.5 million	5%

The key drivers contributing to the top-line performance include:

• Record Net Revenue of C$70.8 million in Q3 2025.
• International sales growth of 208% year-over-year.
• Positive Free Cash Flow generation of $5.0 million in Q3 2025.
• Market leadership in key categories like vapes and pre-rolls.
• Synergies from the Motif acquisition contributing to margin improvement.